Zytiga

Zytiga is a brand name of abiraterone, approved by the FDA in the following formulation(s):

ZYTIGA (abiraterone acetate - tablet; oral)

• 
  Manufacturer: JANSSEN BIOTECH
  
  Approval date: April 28, 2011
  
  Strength(s): 250MG ^[RLD]

Has a generic version of Zytiga been approved?

No. There is currently no therapeutically equivalent version of Zytiga available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zytiga. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  17-substituted steroids useful in cancer treatment
  Patent 5,604,213
  Issued: February 18, 1997
  Inventor(s): Barrie; Susan E. & Jarman; Michael & Potter; Gerard A. & Hardcastle; Ian R.
  Assignee(s): British Technology Group Limited
  Compounds of the general formula (1) ##STR1## wherein X represents the residue of the A, B and C rings of a steroid, R represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R.sup.14 represents a hydrogen atom and R.sup.15 represents a hydrogen atom or an alkyl or alkoxy group of 1-4 carbon atoms, or a hydroxy or alkylcarbonyloxy group of 2 to 5 carbon atoms or R.sup.14 and R.sup.15 together represent a double bond, and R.sup.16 represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, in the form of the free bases or phannaceutically acceptable acid addition salts, are useful for treatment of androgen-dependent disorders, especially prostatic cancer, and also oestrogen-dependent disorders such as breast cancer.
  
  Patent expiration dates:
  
  
  • February 18, 2014
    
    ✓ 
    Patent use: USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 28, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Zytiga Consumer Information (Drugs.com)
• Zytiga Suspension Consumer Information (Wolters Kluwer)
• Zytiga Consumer Information (Cerner Multum)
• Zytiga Advanced Consumer Information (Micromedex)
• Abiraterone Consumer Information (Cerner Multum)
• Abiraterone Advanced Consumer Information (Micromedex)